Annual Cash & Cash Equivalents
$26.68 M
-$28.84 M-51.95%
December 1, 2024
Summary
- As of February 24, 2025, VKTX annual cash & cash equivalents is $26.68 million, with the most recent change of -$28.84 million (-51.95%) on December 1, 2024.
- During the last 3 years, VKTX annual cash & cash equivalents has risen by +$305.00 thousand (+1.16%).
- VKTX annual cash & cash equivalents is now -51.95% below its all-time high of $55.52 million, reached on December 31, 2023.
Performance
VKTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$26.68 M
-$23.67 M-47.02%
December 1, 2024
Summary
- As of February 24, 2025, VKTX quarterly cash and cash equivalents is $26.68 million, with the most recent change of -$23.67 million (-47.02%) on December 1, 2024.
- Over the past year, VKTX quarterly cash and cash equivalents has stayed the same.
- VKTX quarterly cash and cash equivalents is now -86.36% below its all-time high of $195.58 million, reached on March 31, 2024.
Performance
VKTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
VKTX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -52.0% | 0.0% |
| 3 y3 years | +1.2% | 0.0% |
| 5 y5 years | +218.4% | 0.0% |
VKTX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -52.0% | +1.2% | -86.4% | +114.2% |
| 5 y | 5-year | -52.0% | +218.4% | -86.4% | +589.3% |
| alltime | all time | -52.0% | -100.0% | -86.4% | >+9999.0% |
Viking Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $26.68 M(-51.9%) | $26.68 M(-47.0%) |
| Sep 2024 | - | $50.35 M(+14.6%) |
| Jun 2024 | - | $43.91 M(-77.5%) |
| Mar 2024 | - | $195.58 M(+252.3%) |
| Dec 2023 | $55.52 M(+51.6%) | $55.52 M(+49.3%) |
| Sep 2023 | - | $37.19 M(-46.5%) |
| Jun 2023 | - | $69.52 M(+278.6%) |
| Mar 2023 | - | $18.36 M(-49.9%) |
| Dec 2022 | $36.63 M(+38.9%) | $36.63 M(+24.6%) |
| Sep 2022 | - | $29.41 M(+81.2%) |
| Jun 2022 | - | $16.23 M(+30.3%) |
| Mar 2022 | - | $12.45 M(-52.8%) |
| Dec 2021 | $26.37 M(-9.4%) | $26.37 M(+134.1%) |
| Sep 2021 | - | $11.26 M(+27.6%) |
| Jun 2021 | - | $8.83 M(-47.5%) |
| Mar 2021 | - | $16.80 M(-42.3%) |
| Dec 2020 | $29.12 M(+247.6%) | $29.12 M(+652.4%) |
| Sep 2020 | - | $3.87 M(-79.4%) |
| Jun 2020 | - | $18.79 M(+23.1%) |
| Mar 2020 | - | $15.26 M(+82.2%) |
| Dec 2019 | $8.38 M | $8.38 M(-72.9%) |
| Sep 2019 | - | $30.95 M(+61.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2019 | - | $19.12 M(+33.3%) |
| Mar 2019 | - | $14.34 M(-42.1%) |
| Dec 2018 | $24.78 M(+175.7%) | $24.78 M(-85.4%) |
| Sep 2018 | - | $169.51 M(+389.8%) |
| Jun 2018 | - | $34.61 M(-4.8%) |
| Mar 2018 | - | $36.36 M(+304.5%) |
| Dec 2017 | $8.99 M(+192.2%) | $8.99 M(+250.0%) |
| Sep 2017 | - | $2.57 M(-24.3%) |
| Jun 2017 | - | $3.39 M(-22.1%) |
| Mar 2017 | - | $4.36 M(+41.7%) |
| Dec 2016 | $3.08 M(+300.2%) | $3.08 M(+0.7%) |
| Sep 2016 | - | $3.05 M(-40.8%) |
| Jun 2016 | - | $5.16 M(+30.3%) |
| Mar 2016 | - | $3.96 M(+415.1%) |
| Dec 2015 | $768.50 K(+1.7%) | $768.50 K(-64.1%) |
| Sep 2015 | - | $2.14 M(-77.5%) |
| Jun 2015 | - | $9.50 M(+2804.3%) |
| Mar 2015 | - | $327.00 K(-56.7%) |
| Dec 2014 | $755.90 K(+320.9%) | $755.90 K(-15.2%) |
| Jun 2014 | - | $891.50 K(+1031.3%) |
| Mar 2014 | - | $78.80 K |
| Dec 2013 | $179.60 K(>+9900.0%) | - |
| Dec 2012 | $0.00 | - |
FAQ
- What is Viking Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Viking Therapeutics?
- What is Viking Therapeutics annual cash & cash equivalents year-on-year change?
- What is Viking Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Viking Therapeutics?
- What is Viking Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Viking Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of VKTX is $26.68 M
What is the all time high annual cash & cash equivalents for Viking Therapeutics?
Viking Therapeutics all-time high annual cash & cash equivalents is $55.52 M
What is Viking Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, VKTX annual cash & cash equivalents has changed by -$28.84 M (-51.95%)
What is Viking Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VKTX is $26.68 M
What is the all time high quarterly cash and cash equivalents for Viking Therapeutics?
Viking Therapeutics all-time high quarterly cash and cash equivalents is $195.58 M
What is Viking Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, VKTX quarterly cash and cash equivalents has changed by $0.00 (0.00%)